Date published 
February 2012 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Hematological Cancer Therapies: Pipelines, Markets, and Business Considerations - Table of Contents

 

Executive Summary 

Chapter 1
INTRODUCTION
1.1. Background
1.2. Scope of the Report
 

Chapter 2
REVIEW OF HEMATOLOGICAL CANCERS (BLOOD CANCERS)
2.1. Leukemia

Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myelogenous (Myeloid) Leukemia (AML)
Chronic Myelogenous (Myeloid) Leukemia (CML)
Other Types of Leukemia
2.2. Lymphoma
Hodgkin's Disease
Non-Hodgkin's Lymphoma (NHL)
Updated REAL/WHO Classification of Lymphoproliferative Neoplasms
PDQ Modification of REAL Classification of Lymphoproliferative Diseases
2.3. Myeloma
2.4. Myelodysplastic Syndromes (MDS)
2.5. Myeloproliferative Diseases
 

Chapter 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1. Leukemia

Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myelogenous (Myeloid) Leukemia (AML)
Chronic Myelogenous (Myeloid) Leukemia (CML)
Other Types of Leukemia
3.2. Lymphoma
Hodgkin's Disease
Non-Hodgkin's Lymphoma (NHL)
3.3. Myeloma
3.4. Myelodysplastic Syndromes (MDS)
3.5. Myeloproliferative Diseases
 

Chapter 4
EMERGING THERAPIES FOR LEUKEMIA
4.1. Abbott’s Navitoclax
4.2. ARIAD Pharmaceuticals’ Ponatinib
4.3. Astellas Pharma’s and Ambit Biosciences’ Quizartinib
4.4. Boehringer Ingelheim’s Volasertib
4.5. Celator Pharmaceutical’s CPX-351
4.6. Celgene’s REVLIMID
4.7. Chroma Therapeutics’ and Cell Therapeutics’ Tosedostat
4.8. Clavis Pharma’s Elacytarabine
4.9. Cyclacel Pharmaceuticals’ Sapacitabine
4.10. CytRx’ Bafetinib
4.11. Eisai’s and Janssen-Cilag’s Dacogen
4.12. EpiCept’s Ceplene
4.13. Genzyme’s/Sanofi’s Clolar
4.14. Gilead Sciences’ GS 1101
4.15. GlaxoSmithKline’s ARZERRA
4.16. Medac GmbH’s Treosulfan
4.17. Memgen’s ISF35
4.18. Micromet’s Blinatumomab [Micromet is being acquired by Amgen.]
4.19. Mundipharma’s and BioCryst Pharmaceuticals’ Forodesine
4.20. Novartis’ Midostaurin
4.21. Pfizer’s Bosutinib
4.22. Pharmacyclics’ PCI-32765
4.23. Roche’s RG7159 (Obinutuzumab)
4.24. Sunesis Pharmaceuticals’ Vosaroxin
4.25. Syndax Pharmaceuticals’ Entinostat
4.26. Talon Therapeutics’ Marqibo
 

Chapter 5
EMERGING THERAPIES FOR LYMPHOMA
5.1. 4SC AG's Resminostat
5.2. Abbott's and Genentech/Roche's Navitoclax
5.3. Allos Therapeutics' Folotyn
5.4. Astellas Pharma's YM155
5.5. BioCryst Pharmaceutical's Forodesine
5.6. Biovest International/Accentia Biopharmaceuticals' BiovaxID
5.7. Celgene's REVLIMID
5.8. Cell Therapeutics' Pixantrone
5.9. Eli Lilly's Enzastaurin
5.10. Gilead Sciences' GS 1101
5.11. GlaxoSmithKline's ARZERRA
5.12. Kyowa Hakko Kirin's KW-0761
5.13. Memgen's ISF35
5.14. Novartis' Afinitor
5.15. Novartis' Panobinostat
5.16. Pfizer's Inotuzumab Ozogamicin
5.17. Pharmacyclics' PCI-32765
5.18. Plexxikon's (and Daiichi Sankyo's) PLX3397
5.19. Roche's RG7159 (Obinutuzumab)
5.20. Sanofi's SAR245409
5.21. Spectrum Pharmaceuticals' and Topotarget's Belinostat
5.22. Syndax Pharmaceuticals' Entinostat
5.23. Telik's TELCYTA
5.24. Teva Pharmaceutical Industries' and CureTech's CT-011
 

Chapter 6
EMERGING THERAPIES FOR MYELOMA
6.1. Æterna Zentaris' and Keryx Biopharmaceuticals' Perifosine (KRX-1401)
6.2. Bristol-Myers Squibb's and Abbott's Elotuzumab
6.3. Celgene's Actimid
6.4. Geron's Imetelstat
6.5. Janssen Biotech's Siltuximab (CNTO 328)
6.6. Novartis' BHQ880
6.7. Novartis' Panobinostat
6.8. Onyx Pharmaceuticals' Carfilzomib
6.9. PharmaMar's Aplidin
 

Chapter 7
EMERGING THERAPIES FOR MYELODYSPLASTIC SYNDROMES
7.1. Amgen's Nplate (Romiplostim)
7.2. Celgene's REVLIMID
7.3. Cyclacel Pharmaceuticals' Sapacitabine
7.4. Medac GmbH's Treosulfan
7.5. Onconova Therapeutics' ESTYBON (Rigosertib); SymBio Pharmaceuticals' Rigosertib
7.6. Telik's TELINTRA
 

Chapter 8
EMERGING THERAPIES FOR MYELOPROLIFERATIVE DISEASES
8.1. Celgene's Actimid
8.2. Geron's Imetelstat
8.3. Gilead Sciences' GS 6624
8.4. Incyte's and Novartis' Ruxolitinib
8.5. Infinity Pharmaceuticals' IPI-926
8.6. Sanofi's SAR302503
8.7. YM Biosciences' CYT387
 

Chapter 9
BUSINESS CONSIDERATIONS
9.1. Current Sales of Drugs for Treatment of Hematological Cancers
9.2. Personalized Medicine in the Field of Hematological Cancers
9.3. Selected Challenges and Hurdles Being Faced by Companies in the Field of Hematological Cancers
 

Chapter 10
EXPERT INTERVIEWS

10.1. Patrick A. Baeuerle, PhD, Chief Scientific Officer and Senior Vice President, Research & Development, Micromet
10.2. Steven A. Kriegsman, President and Chief Executive Officer David J. Haen, Vice President, Business Development, CytRx Corporation
10.3. Peter Nielsen, President and Chief Executive Officer, Bio-Path Holdings
10.4. Spiro Rombotis, President and Chief Executive Officer, Cyclacel Pharmaceuticals
10.5. Dan Weinseimer, Director, Strategic Marketing and Corporate Development, Sunesis Pharmaceuticals
10.6. David E. Weng, M.D., Ph.D., Chief Medical Officer, TetraLogic Pharmaceuticals

References 

Appendix: Selected Companies Developing Drugs for Hematological Cancers (General) 

Company Index 

About Cambridge Healthtech Institute